This is a double-blind, placebo-controlled, study evaluating a 25 mg dose of CTI-1601.~This study will consist of 1 cohort with 12 to 15 subjects participating in the cohort. Subjects will be dosed once daily (QD) for 14 days followed by dosing every other day (QOD) through Day 28.
To evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) administration of CTI-1601 over 28 days in subjects with Friedreich's ataxia (FRDA).